H.C. Wainwright analyst Yi Chen reiterated a Buy rating on Motus Gi Holdings (MOTS – Research Report) today and set a price target of $2.50. The company’s shares closed yesterday at $0.55.
According to TipRanks, Chen is an analyst with an average return of -30.5% and a 24.74% success rate. Chen covers the Healthcare sector, focusing on stocks such as EyePoint Pharmaceuticals, Clearside Biomedical, and Anixa Biosciences.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Motus Gi Holdings with a $2.50 average price target.
See Insiders’ Hot Stocks on TipRanks >>
The company has a one-year high of $4.81 and a one-year low of $0.55. Currently, Motus Gi Holdings has an average volume of 380.1K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Motus GI Holdings, Inc. is a medical technology company, which is dedicated to improving endoscopy outcomes and experiences. It engages in the development and commercialization of the Pure-Vu System to improve the colonoscopy experience and assist in the early detection and prevention of colorectal cancer and other diseases of the rectum and colon. The company was founded in September, 2016 and is headquartered in Fort Lauderdale, FL.
Read More on MOTS:
- Motus GI Reports Second Quarter 2023 Financial Results and Provides Corporate Update
- Motus GI Holdings reports Q2 EPS (40c), consensus (61c)
- Motus GI Receives Approval from the Israeli Ministry of Health to Initiate Commercial Sales of its Pure-Vu® EVS System
- Motus GI receives approval from Israeli MOH to initiate sales of Pure-Vu
- Motus GI announces purchase agreement for Pure-Vu System from Banner Desert
